Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers.
Similar to our aging society, dogs live longer than before and an increasing number of them die from cancer nowadays. As seen in humans, dogs have malignant cancers that cannot be treated by existing therapies such as surgery, radiotherapy and chemotherapy. Oral malignant melanoma (OMM), a highly invasive cancer in dogs, is one such example.
In humans, some malignant cancer cells express PD-L1 proteins that bind to their receptor PD-1 on T cells, resulting in the suppression of the T cell’s immune function. Thus, PD-L1/PD-1 interaction is considered an “immune escape mechanism” that cancer cells have. Antibodies that block PD-1/PD-L1 binding have proven effective in inducing anti-tumor immune responses and have been widely used in immunotherapy in the last five years. However, in dogs, no such clinical studies have been reported so far.
Professor Satoru Konnai of Hokkaido University and his collaborators in Japan have developed a chimeric anti-PD-L1 antibody that induces immune responses and therefore tumor regression in dogs with malignant cancers.
The team first revealed that PD-L1 is expressed in the cells of OMM and another type of cancer called undifferentiated sarcoma, confirming that those two cancers are likely targeted by the immunotherapy. They then utilized a rat anti-PD-L1 antibody to develop a rat-dog chimeric antibody which should help avoid rejection by the immune system and allergic reactions when administered to dogs.
In their pilot clinical study, seven dogs with OMM and two dogs with undifferentiated sarcoma were treated with the chimeric antibody every two weeks. One of the OMM dogs showed obvious tumor regression after ten weeks of administration while one dog with undifferentiated sarcoma showed a significant decrease in tumor burden after three weeks. None of them showed adverse effects such as an allergic reaction. Moreover, their data suggested the treatment may have prolonged survival in dogs with OMM after pulmonary metastasis.
“Chimerization of the antibody is now proven as a simple and effective strategy to develop therapeutic antibodies in veterinary medicine. Although further clinical studies are needed, other PD-L1-positive cancers could be targeted by the antibody we have developed,” says Satoru Konnai. “Given the similarity between humans and dogs in cancer biology, our study should provide a beneficial model for human preclinical studies.”
Learn more: New therapeutic antibody for dog cancers
The Latest on: Chimeric antibody
- Monoclonal Antibody Therapy Market Size Analysis, Revenue Status, Growth Factors, Demand, Top 20 Countries Data with Forecast to 2023 on February 13, 2019 at 10:48 pm
Regarding source, the market has been segmented into chimeric, human, humanized, recombinant, and other. Regional Analysis for Global Monoclonal Antibody Therapy Market The regional segmentation of th... […]
- Improvement of antibody functionality by structure-guided paratope engraftment on February 13, 2019 at 2:44 am
The interactive quaternary surface is delineated by solving the crystal structure of two FR3 loop-chimeric antibodies. Chimerization enhances the neutralizing activity of several potent bNAbs against ... […]
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit on February 8, 2019 at 9:37 am
A 42-year old man with heavily-pretreated relapsed Philadelphia chromosome-positive, CD19-positive, pre-B acute lymphoblastic leukemia who was previously treated with CD19 chimeric antigen ... a monoc... […]
- Bispecific, Multispecific Antibodies Grapple with Cancer on February 7, 2019 at 9:01 am
most strikingly in the direction of checkpoint inhibition and chimeric antigen receptor (CAR) T-cell therapy. Another front, however, is about to see its share of action. Here, newly engineered bispec... […]
- Optimizing Immunotherapy Lead Selection on February 7, 2019 at 3:58 am
Chimeric antigen receptor (CAR) T-cell and bispecific antibody immunotherapies hold enormous potential for the treatment of cancer. But not all patients benefit from these therapies, especially those ... […]
- The Evolution of Antibody Patents on October 8, 2018 at 4:30 am
Centocor had used a mouse model to develop its antibody and then combined that mouse antibody with human elements to make a chimeric antibody. However, in its patent, while it disclosed and characteri... […]
- Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection on August 8, 2018 at 11:55 am
1 Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands. 2 Department of Molecular and Cell Biology, National Center for Biotechnology–Spanish National Research Council (CNB-CSIC), ... […]
- Monoclonal Antibodies Market 2018 - Leading Products in the Chimeric, Humanized, and Human Market on April 12, 2018 at 10:41 am
The " What's Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])" re... […]
via Google News and Bing News